rejuvant life tabs

AgeX-Ohio State collaborate on diabetes therapy

Latest articles

Leucine, weight loss and NAD+ boosting

Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine. In the first part of...

Organoid to the rescue of the thyroid

Sci-fi or reality? Artificial organs may soon be the solution for those suffering from all forms of hypothyroidism. The role of the thyroid gland is...

Changing demographics warrant solid longevity foundation

EU Green Paper on Ageing is a wish list, but the European Longevity Initiative is proposing a foundation first. Back in January, the European Commission...

Longevity supplements report: JUVICELL profile

Determined to bring longevity opportunities to a wider market, JUVICELL packs ten ingredients into its longevity supplement. Over the coming weeks, we will be bringing...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

Leucine, weight loss and NAD+ boosting

Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine. In the first part of...

Organoid to the rescue of the thyroid

Sci-fi or reality? Artificial organs may soon be the solution for those suffering from all forms of hypothyroidism. The role of the thyroid gland is...

Changing demographics warrant solid longevity foundation

EU Green Paper on Ageing is a wish list, but the European Longevity Initiative is proposing a foundation first. Back in January, the European Commission...
Rejuvant

AgeX Therapeutics set to collaborate with The Ohio State University to generate proof-of-concept animal data for AgeX’s brown adipose tissue (BAT) cell therapy candidate for diabetes and obesity.

AgeX Therapeutics, a biotech developing therapeutics for human aging and regeneration, announced today a research collaboration with The Ohio State University using AgeX’s brown adipocyte tissue (BAT) cell therapy candidate AgeX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity, metabolic health including glucose metabolism and cardiac function.

Longevity.Technology: Diabetes and obesity are significant threats to both lifespan and healthspan, and their prevalence has been increasing year on year. AgeX specifically targets metabesity – the constellation of interconnected diseases with metabolic roots – with AGEX-BAT1, lining up type 2 diabetes and age-related metabolic disorders in its sights.

The research will be conducted in the laboratory of world-leading BAT researcher Kristin Stanford, PhD, Associate Professor in Physiology & Cell Biology and Associate Director of the Diabetes and Metabolism Research Center at The Ohio State University Wexner Medical Center.

Kristen Stanford, PhD, associate professor at OSU
Kristen Stanford, PhD, Associate Professor at OSU

As an early pioneer in BAT transplantation, Dr Stanford transplanted BAT from donor mice into recipient mice. By 8–12 weeks post transplantation, recipient mice had improved glucose tolerance, increased insulin sensitivity, lower body weight, reduced fat mass, and a full reversal of high-fat diet-induced insulin resistance [1]. This year, Dr Stanford became the first person to show a direct role for BAT to enhance cardiac function [2].

“We will be investigating the potential of human pluripotent stem cell-derived brown adipose tissue (BAT) to improve metabolic health and cardiac function.” said Dr Stanford. “The preclinical research studies may provide the basis for future therapeutic interventions in diabetes and obesity as well as provide new insights into the role of BAT.”

Elevant

AgeX’s BAT cells may have advantages over other sources of BAT given published data show that AgeX’s pioneering PureStem® cell derivation and manufacturing technology platform is able to generate highly pure and scalable BAT cells, potentially providing an unlimited source of cells [3]. AgeX-BAT1 consists of BAT progenitor cells that are capable of becoming BAT.

 


 

“The preclinical research studies may provide the basis for future therapeutic interventions in diabetes and obesity as well as provide new insights into the role of BAT.”

 


 

“We are delighted to collaborate with Dr Kristin Stanford, who has dedicated her career to understanding brown adipose tissue (BAT). The research could generate proof-of-concept data in an animal model for AgeX’s BAT cell therapy candidate AgeX-BAT1,” said Dr Nafees Malik, Chief Operating Officer of AgeX. “AgeX’s BAT cells may offer an innovative therapeutic strategy for diabetes and obesity, which present potential multi-billion-dollar market opportunities, given 13% of adults in the US suffer from diabetes and 42% from obesity.”

Find out more about AgeX’s potential merger with LyGenesis HERE.

Elevant

[1] https://pubmed.ncbi.nlm.nih.gov/23221344/
[2] https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.049813
[3] https://stemcellres.biomedcentral.com/articles/10.1186/s13287-018-1087-7

Images courtesy of AgeX and OSE

Comment on this article

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

Renal fibrosis caused by telomere shortening – new research

CNIO researchers demonstrate that renal fibrosis is caused by telomere shortening, paving the way for future treatment. Researchers in the Telomeres and Telomerase Group at...

Successful free radical therapy? Targeting is key

SFRRI President-Elect Giovanni Mann reveals why targeting cellular antioxidant pathways needs to be as precise as possible – and how this could lead to...

Gut microbiome plays a role in healthy aging and longevity

A new, large study on the gut microbiome shows promising new data about gut aging and longevity. Healthy aging and a long life is on...

Regeneration technique makes old blood young again

Restoring blood component regeneration process could be just like changing the oil in a car. A research team at the University of Colorado Anschutz Medical...

Gut bacteria start-up exits stealth with unique data

Wild Biotech plans to use database of more than 1,200 gut microbes to pursue novel drugs for human diseases and enhance CRISPR editing. Wild Biotech,...
Supps report ad middle